Abigail Brooks, MA

Data from the phase 3 study confirmed the lot consistency, immunogenicity, safety, and tolerability of a toxoid-based Clostridioides difficile vaccine.

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with ulcerative colitis and decreased C-reactive protein levels in patients with Crohn disease.

Household primary language was associated with vision screening, with children from non-English households exhibiting lower rates of pediatric vision screening.

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared with those without IBS.

Results showed higher-exposure dupilumab met the study’s primary endpoint for peak esophageal intraepithelial count ≤6 eos/high-power field.

Results highlighted a growing number of incident cases of asthma, inflammatory bowel disease, multiple sclerosis, psoriasis, atopic dermatitis, and rheumatoid arthritis from 1990 to 2019.

Age, fecal calprotectin level, toxin B polymerase chain reaction cycle threshold, immunosuppression, sex, and creatinine levels were identified as independent risk factors for developing recurrent Clostridioides difficile infection.

Annualized costs for the 24-month study period were highest among patients with both NASH and T2D, highlighting the incremental cost of adding an additional diagnosis for comorbid NASH or T2D.

Study results suggest the greatest risk for Clostridioides difficile infection was observed with use of clindamycin while the lowest risk was observed with doxycycline and minocycline.